Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

In the latest twist in its efforts to wrap up years of high-profile opioid litigation, the billionaire family behind the ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions while managing to stay true to its patient-centric ethos along the way. | Some six and a ...

One of the 30-second spots taps into the intensity of hit shows like “Game of Thrones.” It starts with a medieval royal preparing to go to war in the name of colorectal cancer screening, declaring, ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

The Preeclampsia Foundation has found a formula for closing the maternal health equity gap: Mix one part equity-forward preeclampsia education with one part low-dose aspirin prophylaxis and voilà, you ...

With the purchase of a former Lonza biologics plant now in the books, San Francisco-based CDMO Joinn Biologics is expanding from one Bay Area to another. | CDMO Joinn Biologics has completed its ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...